{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hemophilia",
    "query": {
      "condition": "Hemophilia"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 347,
    "total_pages": 35,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hemophilia&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-21T23:18:30.327Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02585960",
      "title": "BAX 855 PK-guided Dosing",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "PEGylated Recombinant Factor VIII",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "12 Years to 65 Years"
      },
      "enrollment_count": 135,
      "start_date": "2015-11-23",
      "completion_date": "2018-08-05",
      "has_results": true,
      "last_update_posted_date": "2021-05-25",
      "last_synced_at": "2026-05-21T23:18:30.327Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02585960"
    },
    {
      "nct_id": "NCT01341912",
      "title": "Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Severe Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Human-cl rhFVIII",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "12 Years to 65 Years · Male only"
      },
      "enrollment_count": 3,
      "start_date": "2011-06",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2020-03-17",
      "last_synced_at": "2026-05-21T23:18:30.327Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01341912"
    },
    {
      "nct_id": "NCT05500807",
      "title": "Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Von Willebrand Disease, Type 3",
        "Concomitant VWD and Hemophilia"
      ],
      "interventions": [
        {
          "name": "Emicizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bleeding and Clotting Disorders Institute Peoria, Illinois",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "0 Years to 90 Years"
      },
      "enrollment_count": 40,
      "start_date": "2022-11-01",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-05-21T23:18:30.327Z",
      "location_count": 12,
      "location_summary": "Orange, California • Redwood City, California • Coral Gables, Florida + 9 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05500807"
    },
    {
      "nct_id": "NCT01757405",
      "title": "Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A",
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "Recombinant Factor VIIa BI (rFVIIa BI)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "12 Years to 65 Years · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2013-02-20",
      "completion_date": "2014-11-11",
      "has_results": true,
      "last_update_posted_date": "2021-05-11",
      "last_synced_at": "2026-05-21T23:18:30.327Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01757405"
    },
    {
      "nct_id": "NCT00623727",
      "title": "BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "rFVIII-FS/pegylated liposomes (BAY79-4980)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rFVIII-FS/WFI (BAY14-2222)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "70 Years",
        "sex": "MALE",
        "summary": "12 Years to 70 Years · Male only"
      },
      "enrollment_count": 143,
      "start_date": "2008-06",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2013-07-15",
      "last_synced_at": "2026-05-21T23:18:30.327Z",
      "location_count": 20,
      "location_summary": "Orange, California • Sacramento, California • San Francisco, California + 17 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00623727"
    },
    {
      "nct_id": "NCT01405742",
      "title": "Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Severe Hemophilia A"
      ],
      "interventions": [
        {
          "name": "rF.VIII",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 4,
      "start_date": "2012-07",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2016-10-07",
      "last_synced_at": "2026-05-21T23:18:30.327Z",
      "location_count": 6,
      "location_summary": "Washington D.C., District of Columbia • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01405742"
    },
    {
      "nct_id": "NCT03054389",
      "title": "Non-Interventional Study to Capture the Patient Experience on Gene Therapy for Hemophilia Within the AskBio009-101 Study Through Patient and Investigator Interviews",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "Qualitative Interview - Participants/ Patients",
          "type": "OTHER"
        },
        {
          "name": "Qualitative Interview - Investigators and Study Coordinators",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 27,
      "start_date": "2017-03-31",
      "completion_date": "2017-06-06",
      "has_results": false,
      "last_update_posted_date": "2021-04-23",
      "last_synced_at": "2026-05-21T23:18:30.327Z",
      "location_count": 1,
      "location_summary": "Cambridge, Massachusetts",
      "locations": [
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03054389"
    },
    {
      "nct_id": "NCT04030052",
      "title": "Emicizumab PUPs and Nuwiq ITI Study",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Nuwiq (low dose protocol)",
          "type": "DRUG"
        },
        {
          "name": "HEMLIBRA",
          "type": "DRUG"
        },
        {
          "name": "Nuwiq (Atlanta protocol)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 0,
      "start_date": "2022-02-17",
      "completion_date": "2023-01-19",
      "has_results": false,
      "last_update_posted_date": "2024-01-05",
      "last_synced_at": "2026-05-21T23:18:30.327Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04030052"
    },
    {
      "nct_id": "NCT00195221",
      "title": "Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia B",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia B",
        "Allergic Reactions"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 166,
      "start_date": "2005-02",
      "completion_date": "2007-11",
      "has_results": false,
      "last_update_posted_date": "2007-12-05",
      "last_synced_at": "2026-05-21T23:18:30.327Z",
      "location_count": 15,
      "location_summary": "Phoenix, Arizona • Orange, California • Atlanta, Georgia + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00195221"
    },
    {
      "nct_id": "NCT01708564",
      "title": "A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hemophilia"
      ],
      "interventions": [
        {
          "name": "rhFVIIa",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "rEVO Biologics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "MALE",
        "summary": "18 Years to 75 Years · Male only"
      },
      "enrollment_count": 15,
      "start_date": "2012-10",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2013-07-30",
      "last_synced_at": "2026-05-21T23:18:30.327Z",
      "location_count": 2,
      "location_summary": "Sacramento, California • Chicago, Illinois",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01708564"
    }
  ]
}